The endocannabinoid system in cardiovascular function: novel insights and clinical implications

Area of Science:

• Cardiovascular Research
• Endocannabinoid System Biology
• Pharmacology

Background:

• Cardiovascular disease is a leading global cause of death, with increasing at-risk populations.
• The endocannabinoid (eCB) system, including receptors and ligands, is implicated in cardiovascular regulation and disorders.
• Dysregulation of the eCB system plays a key role in various cardiovascular conditions.

Purpose of the Study:

• To review current literature on the endocannabinoid system's role in cardiovascular function and disease.
• To explore novel compounds and potential interventions targeting the eCB system for cardiovascular disorders.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of research on cannabinoid receptors (CB1R, CB2R), TRPV1, and PPARs.
• Examination of pharmacological manipulation of the eCB system.

Main Results:

• Drugs targeting CB1R, CB2R, TRPV1, and PPARs show efficacy in animal models of hypertension, atherosclerosis, and myocardial infarction.
• Despite past clinical trial setbacks, preclinical development of selective eCB-targeting drugs is advancing with promising, safer results.
• The eCB system influences blood pressure, cardiac contractility, and endothelial function.

Conclusions:

• Growing evidence confirms the eCB system's critical role in cardiovascular health and disease.
• Novel therapeutic targets and drugs are emerging, but require collaborative efforts for successful clinical translation.